150 related articles for article (PubMed ID: 25132026)
21. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
22. The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer.
Kim SG; Hwang SH
World J Surg Oncol; 2016 Apr; 14():102. PubMed ID: 27039375
[TBL] [Abstract][Full Text] [Related]
23. [Clinical Impact of adjuvant chemotherapy in patients with T1N2/3 Gastric cancer].
Tsuchida K; Kunisaki C; Watanabe T; Ono H; Oshima T; Fukushima T; Yoshikawa T; Rino Y; Imada T; Masuda M
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2239-41. PubMed ID: 25731482
[TBL] [Abstract][Full Text] [Related]
24. Facilitated completion of 1-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer by medical oncologists.
Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Ida S; Kumagai K; Sano T; Nunobe S
Surg Today; 2020 Oct; 50(10):1197-1205. PubMed ID: 32240378
[TBL] [Abstract][Full Text] [Related]
25. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
Cho JH; Lim JY; Cho JY
PLoS One; 2017; 12(10):e0186362. PubMed ID: 29040299
[TBL] [Abstract][Full Text] [Related]
26. Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer.
Jeong JH; Ryu MH; Ryoo BY; Lee SS; Park I; Lee SH; Kim KC; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2012 Oct; 70(4):523-9. PubMed ID: 22864947
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
[TBL] [Abstract][Full Text] [Related]
28. A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC).
Ueda Y; Fujimura T; Kinami S; Hirono Y; Yamaguchi A; Naitoh H; Tani T; Kaji M; Yamagishi H; Miwa K;
Jpn J Clin Oncol; 2006 Aug; 36(8):519-22. PubMed ID: 16803844
[TBL] [Abstract][Full Text] [Related]
29. Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer.
Hasegawa H; Fujitani K; Kurokawa Y; Hirao M; Nakazuru S; Mita E; Tsujinaka T
Chemotherapy; 2010; 56(6):436-43. PubMed ID: 21088394
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of patients with advanced gastric cancer undergoing S-1/CDDP combined neoadjuvant chemotherapy].
Kikuchi D; Ishii Y; Saitou M; Yamada M; Takenoshita S
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1113-7. PubMed ID: 21772093
[TBL] [Abstract][Full Text] [Related]
31. [Postoperative adjuvant chemotherapy for gastric cancer after the adjuvant chemotherapy trial of S-1 for gastric cancer in Hiroshima prefecture: results from a questionnaire survey and future challenges].
Yamaguchi K; Hirabayashi N; Ninomiya M; Shinozaki K; Hatanaka N; Matsuda H; Tanabe K
Gan To Kagaku Ryoho; 2013 Dec; 40(13):2555-9. PubMed ID: 24335369
[TBL] [Abstract][Full Text] [Related]
32. Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002).
Fujitani K; Tamura S; Kimura Y; Matsuyama J; Imamura H; Yamamoto K; Fujita J; Iijima S; Ueda S; Kurokawa Y; Shimokawa T; Satoh T;
Gastric Cancer; 2020 May; 23(3):520-530. PubMed ID: 31667688
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study).
Kodera Y; Ito S; Mochizuki Y; Kondo K; Koshikawa K; Suzuki N; Kojima H; Kojima T; Matsui T; Takase T; Tsuboi K; Fujiwara M; Nakao A;
Eur J Surg Oncol; 2009 Nov; 35(11):1158-63. PubMed ID: 19328643
[TBL] [Abstract][Full Text] [Related]
34. [The future of loco-regional treatment for advanced gastric cancer].
Nagahama T; Ando M; Ganno H; Ami K; Fukuda A; Maruyama M
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2012-4. PubMed ID: 19106507
[TBL] [Abstract][Full Text] [Related]
35. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Ito S; Ohashi Y; Sasako M
BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
[TBL] [Abstract][Full Text] [Related]
36. Improved Efficacy by Addition of Protein-bound Polysaccharide K to Adjuvant Chemotherapy for Advanced Gastric Cancer.
Fukuchi M; Mochiki E; Ishiguro T; Ogura T; Sobajima J; Kumagai Y; Ishibashi K; Ishida H
Anticancer Res; 2016 Aug; 36(8):4237-41. PubMed ID: 27466538
[TBL] [Abstract][Full Text] [Related]
37. A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for stage III/IV gastric cancer (CCOG 1106).
Kurimoto K; Ishigure K; Mochizuki Y; Ishiyama A; Matsui T; Ito S; Nakayama H; Tanaka N; Kobayashi D; Sakamoto J; Nakao A; Kodera Y
Gastric Cancer; 2015 Apr; 18(2):354-9. PubMed ID: 24838732
[TBL] [Abstract][Full Text] [Related]
38. [Neoadjuvant chemotherapy with combined S-1 plus weekly low-dose cisplatin followed by surgical resection for advanced gastric cancer].
Isobe T; Hashimoto K; Kizaki J; Miyagi M; Aoyagi K; Koufuji K; Shirouzu K
Gan To Kagaku Ryoho; 2013 Oct; 40(10):1331-5. PubMed ID: 24105055
[TBL] [Abstract][Full Text] [Related]
39. [Clinical significance of the human epidermal growth factor receptor 2( HER2) in patients with recurrent gastric cancer who received S-1 adjuvant chemotherapy].
Aoyama T; Hayashi T; Fujikawa H; Ogata T; Cho H; Wada H; Kitani Y; Yukawa N; Oshima T; Rino Y; Ozawa Y; Masuda M; Yoshikawa T
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1647-9. PubMed ID: 24393876
[TBL] [Abstract][Full Text] [Related]
40. [The efficacy of neoadjuvant chemotherapy with S-1/CDDP (SP) to the patients with large type 3 and type 4 gastric cancer].
Katayanagi S; Nomura T; Sumi T; Suda T; Hoshino S; Ito K; Takagi Y; Tsuchida A; Kawachi S; Shimazu M
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2214-6. PubMed ID: 24394063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
